CONGRESS ABSTRACT

Background: The clinical benefit of beta-blocker treatment in patients with a previous myocardial infarction (MI) and without a reduced left ventricular ejection fraction (LVEF) is not established. This study aims at assessing the impact of beta-blocker treatment after an MI based on the type of MI at presentation, the…

BACKGROUND Drug-coated balloons (DCB) enable a “leave-nothing-behind” strategy in de novo small-vessel coronary disease, potentially reducing metal burden while maintaining efficacy. We synthesized randomized evidence versus contemporary drug-eluting stents (DES). METHODS Systematic search for randomized controlled trials comparing DCB-only versus DES in de novo small coronary vessels (≤3.0 mm)….

Introduction : OCT is superior to IVUS for assessing correct coronary stent implantation. The few articles in the literature directly comparing OCT and IVUS show an underestimation of OCT diameters and areas from 5 to 14%. The aim of our study is to evaluate the difference between OCT-based diameters…

Background. Lipoprotein(a) [Lp(a)] is a genetically determined cardiovascular risk factor . However, its impact on coronary anatomy, plaque biology, and outcomes after percutaneous coronary intervention (PCI) remains incompletely defined from an interventional perspective. Methods. We performed a systematic review and random-effects meta-analysis of observational studies comparing high versus low…

Introduction Although current European Society of Cardiology guidelines state that a P2Y12 inhibitor pretreatment strategy may be considered in STEMI patients undergoing a primary percutaneous coronary intervention (PCI) strategy (Class IIb), solid evidence to support this choice in clinical practice remains lacking. The aim of this study was to…